Get the Stockscreener App
0.2782
0.29%
-0.0008
Vivosim Labs Inc stock is traded at $0.2782, with a volume of 246.87K.
It is down -0.29% in the last 24 hours and down -24.20% over the past month.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
See More
Previous Close:
$0.279
Open:
$0.2824
24h Volume:
246.87K
Relative Volume:
0.05
Market Cap:
$3.73M
Revenue:
$142.00K
Net Income/Loss:
$-1.23M
P/E Ratio:
0.5974
EPS:
0.4657
Net Cash Flow:
$-10.62M
1W Performance:
-2.49%
1M Performance:
-24.20%
6M Performance:
-85.12%
1Y Performance:
-87.69%
1-Day Range:
$0.2753
$0.284
1-Week Range:
$0.271
$0.2959
52-Week Range:
$0.2625
$5.30
Vivosim Labs Inc Stock (VIVS) Company Profile
Name
Vivosim Labs Inc
Sector
Industry
Phone
858-224-1000
Address
11555 SORRENTO VALLEY ROAD, SAN DIEGO
Compare VIVS vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
0.2782 | 3.72M | 142.00K | -1.23M | -10.62M | 0.4657 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-18 | Initiated | H.C. Wainwright | Buy |
| Nov-10-17 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-25-17 | Initiated | Raymond James | Outperform |
| Aug-11-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Jun-29-15 | Initiated | Jefferies | Buy |
| Jun-29-15 | Initiated | Piper Jaffray | Overweight |
View All
Vivosim Labs Inc Stock (VIVS) Latest News
VivoSim Labs Faces Nasdaq Minimum Bid Price Deficiency - TipRanks
VivoSim Labs Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Warrants keep Esousa, Wachs’ VivoSim Labs (VIVS) stake under 10% - Stock Titan
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains Momentum - Barchart.com
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as - openPR.com
VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus - FinancialContent
VivoSim Labs (VIVS) seeks approval for reverse split, equity plan and warrant repricing - Stock Titan
VivoSim: Fiscal Q1 Earnings Snapshot - marketscreener.com
Oversold Stocks TOON, RMCF, PRSO, OFAL Offer Opportunity – See Why Inside - FinancialContent
VivoSim Labs Ord Shs (VIVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
$VIVS Load up 🔥🚀 - Moomoo
VivoSim Labs, INC. SEC Filing (Aug 11, 2026) - Stock Titan
VivoSim Labs (NASDAQ: VIVS) seeks approval for reverse split, warrant share issuance - Stock Titan
VivoSim Labs (VIVS) News Flow - Moomoo
VIVS PE Ratio & Valuation, Is VIVS Overvalued - Intellectia AI
VIVOSIM LABS Q1 2026 Earnings Preview: Recent $VIVS Insider Trading, Hedge Fund Activity, and More - Moomoo
Stock Splits Calendar for: - Yahoo! Finance Canada
VivoSim Labs regains Nasdaq compliance after cash infusion By Investing.com - Investing.com UK
VivoSim Labs Regains Nasdaq Compliance, Boosts Cash to $10.1M and Projects 500%+ Revenue Growth for 2027 - Minichart
VivoSim Labs regains Nasdaq compliance after cash infusion - Investing.com
🍋💦🍋💦💣🚀 - Moomoo
VivoSim Provides Financial and Listing Compliance Update - The Manila Times
VivoSim regains Nasdaq compliance after $10.1 million cash update - Quiver Quantitative
VivoSim Labs Regains Nasdaq Compliance After $6M Milestone and $4M Financing - TradingView
VivoSim reports 13.4M shares outstanding after July warrant exercises - Stock Titan
VivoSim Labs issues 9,896,718 shares on warrant exercises - Bitget
IPO Databook: VivoSim Labs (VIVS US)Jul 2026 - Smartkarma
VivoSim Labs Sets 2026 Annual Shareholder Meeting Date - The Globe and Mail
VivoSim Labs, Inc. Revenue Breakdown – NASDAQ:VIVS - TradingView
VivoSim Labs (VIVS) Dips 6.89% as Stock Tests Key Support at $0.40Straddle Setup - Vinanet
VIVS|VivoSim Labs Ord Shs|Price:0.413|Chg%:-0.037 - TradingKey
VivoSim Labs Addresses Nasdaq Listing Compliance Concerns - TipRanks
VIVS|VivoSim Labs Ord Shs|Price:0.282|Chg%:-0.035 - TradingKey
VivoSim Labs, Inc. (VIVS) Stock Price, News, Quote & History - Yahoo! Finance Canada
VivoSim Labs, Inc. (VIVS) stock price, news, quote and history - Yahoo Finance UK
VivoSim Labs (VIVS) Holds Steady Near Support at $0.45 Amid Low VolatilityFactor ETF Flow - dars.gov.et
VIVS Expands into China with First Commercial Sales - GuruFocus
VivoSim secures first commercial sales in China market By Investing.com - Investing.com South Africa
VivoSim secures first commercial sales in China market - Investing.com UK
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services - GlobeNewswire
VIVS Q4 2025 Earnings: Massive EPS Miss Sends Shares LowerOperating Income Trends - vinanet.vn
VivoSim Labs Raises $4 Million in At-the-Market Private Placement to Advance 3D Human Tissue Models for Drug Safety Testing 1 – Minichart - Minichart
VivoSim Labs Announces $4 Million Private Placement Financing - TipRanks
VivoSim Labs Prices $4.0 Million Private Placement and Amends Legacy Armistice Warrants - TradingView
VivoSim prices $0.85 warrants in $4 million private placement - Bitget
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor - Sahm
Why is VivoSim Labs stock falling Thursday? - MSN
VivoSim raises $4M in private placement from single healthcare investor - Dealroom
VivoSim Labs raises $4M in private placement - Investing.com India
VivoSim Labs prices USD 4 million private placement at USD 0.85 per share - Bitget
VivoSim Labs raises $4M in private placement By Investing.com - Investing.com Nigeria
Vivosim Labs Inc Stock (VIVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):